364 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1929)
- Addiction (16)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- (-) Autoimmune Disorders (28)
- Blood Disorders (38)
- Bone & Muscle (10)
- Cancer
(749)
- Bladder Cancer (13)
- Brain Cancer (24)
- Breast Cancer (71)
- Gastrointestinal (16)
- Gynecologic Cancer (33)
- Head and Neck Cancer (4)
- Kidney Cancer (8)
- Leukemia (79)
- Liver Cancer (11)
- Lung Cancer (65)
- Lymphoma (46)
- Multiple Myeloma (31)
- Pancreatic Cancer (22)
- (-) Prostate Cancer (36)
- Sarcoma (25)
- (-) Skin Cancer (30)
- Solid Tumors (44)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (37)
- Critical Illness (1)
- Dental (2)
- Developmental Disorders (2)
- Diabetes (22)
- Ear, Nose and Throat (11)
- Endocrine & Metabolic Disease (13)
- Eye (8)
- Gastrointestinal and Digestive Diseases (22)
- Hair and Skin Disorders (2)
- Headaches (5)
- Healthy Volunteers (175)
- Heart Disease (129)
- Infectious Disease (48)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (49)
- Lung Disease (32)
- Meniere's Disease (1)
- Neurological Disorders (176)
- Nutrition (4)
- Obesity (10)
- Obstetrics & Gynecology (52)
- Pain Management (1)
- Pediatrics (104)
- Psychiatric Disorders (65)
- Rehabilitation (8)
- Stroke (7)
- Surgery (7)
- Transplant (51)
- Urology (4)
- Vascular Conditions (9)
Displaying 1 - 94 of 94
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The main purpose of the study is to determine whether the study drug, ONC-392, together with a standard of care drug PLUVICTO (Lutetium Lu 177 Vipivotide Tetraxetan), are safe and well tolerated, and whether two drugs are effective in treating prostate cancer, in comparison with the standard of care PLUVICTO alone. ONC-392 has not yet been approved by the…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to find out the side effects of JNJ-87189401 given in combination with JNJ-78278343 to patients with metastatic castration-resistant prostate cancer, and to find which doses of the two study drugs when given in combination cause the least side effects. The study will also look at how long JNJ-87189401 and JNJ-78278343 stay in…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
You are being invited to take part in a research study that includes studying JNJ-78278343 in subjects with prostate cancer. This is an investigational drug which means that this is a new approach for the treatment of people who have prostate cancer. The main purpose of this study is to find a safe dose of JNJ-78278343 that can be used in the treatment of…
Condition: Skin Cancer / Melanoma
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to identify the safest and most tolerable dose of the study drug, DYP688 that can be given to patients. Also to evaluate how well DYP688 might work in treating certain types of cancer including metastatic uveal melanoma and other melanomas with GNAQ/11 mutations (or genetic changes to the gene GNAQ/11). Metastatic means the…
Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Currently Recruiting
The purpose of this study is to compare V940 plus pembro given after surgery to a placebo plus pembro given after surgery and to study how effective the study drug is. A placebo looks like a study drug, but it has no active ingredients. V940 has not yet been approved by the Food and Drug Administration (FDA). Pembrolizumab is FDA approved but it has not…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness of REGN5678 which will be given alone first and then be given in combination with cemiplimab. Neither REGN5678 nor Cemiplimab is FDA-approved to treat your type of cancer. Cemiplimab is approved by the FDA for the treatment of certain…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The main goal of a research study is to learn things to help patients in the future. The decision to join or not join the research study will not cause you to lose any medical benefits. If you decide not to take part in this study, your doctor will continue to treat you. The purpose of this study is to learn more about prostate cancer and: to describe the…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to assess the efficacy of a home-delivered whole-food plant-based diet (WFPBD) intervention in promoting weight loss in overweight or obese men with prostate cancer receiving androgen deprivation therapy (ADT), as compared to general nutritional counseling only. Another purpose is to assess how easy or difficult it is for…
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Currently Recruiting
The purpose of this study is to develop a cohort of patients with early scleroderma and to collect data on clinical outcomes, radiological tests, laboratory tests, and to obtain biological specimens for testing.
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Currently Recruiting
This research is being done to determine how variations in genes may explain the different risks to develop scleroderma (or CREST) seen in African American patients compared to other populations. People who are African American with scleroderma (or CREST) may join. This research involves a blood draw and physical exams.
Condition: Cancer / Skin Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to see if IMC-F106C, in combination with nivolumab, works better than the standard therapy (nivolumab alone or in combination with relatlimab) at making tumors stop growing or shrink. IMC-F106C has not yet been approved by the Food and Drug Administration (FDA). Nivolumab and the combination of nivolumab + relatlimab is FDA…
Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to see if the combination of fianlimab (REGN3767) and cemiplimab (REGN2810) is an effective treatment compared to pembrolizumab in participants that have had melanoma removal surgery but are still at high risk for the return of the disease. This study involves 2 study drugs: fianlimab (REGN3767) and cemiplimab (REGN2810). The…
Condition: Cancer / Prostate Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to help researchers understand more about the possible effectiveness and safety of apalutamide when given to patients with or without intermittent Androgen Deprivation Therapy (ADT) to treat metastatic Castration-Sensitive Prostate Cancer (mCSPC). Apalutamide is a type of drug that blocks the action of testosterone. By blocking…
Condition: Cancer / Prostate Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
You are being asked to take part in this study because you have been diagnosed with advanced prostate cancer and the standard drugs to treat your disease (metastatic castration-resistant prostate cancer mCRPC) are no longer effective or no effective treatment is known for your type of cancer. This research study will test an investigational drug called CC-…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this research study is to determine the safety and tolerability of XmAb20717 by itself and in combination with other anticancer therapies (Olaparib, Cabazitaxel, Docetaxel, and Carboplatin). XmAb20717 has not been studied in a significant number of humans, therefore, some of its effects are unknown. XmAb20717 is an investigational antibody-…
Condition: Autoimmune Disorders
Investigator: Olatundun Williams, MD
Status: Closed
The purpose of this study is to understand the life course of PIRD patients and their family members that have the same gene change but do not have the same symptoms. PIRD is mostly due to inherited changes in the genes that normally have immune cells fight infections and regulate the immune system. There are many types of problems that patients with PIRD…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to determine how safe the study drug, VTP-850, is in people with prostate cancer who have had initial treatment but whose prostate-specific antigen (PSA) levels have started to rise again. This study also aims to find the appropriate dose regimen of VTP-850 that can be given safely to people with prostate cancer. In addition, we…
Condition: Cancer / Skin Cancer
Investigator: Shaheer Khan, DO
Status: Closed
This trial is being done to look at the effects of RP1 in kidney, liver, heart, and lung transplant recipients with skin cancer. These effects could be good (for example, shrinking of tumors) or bad (called side effects). Researchers will study the effects and how long they last. This study is being done to find out how effective RP1 is in treating the…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to determine whether HB-302/HB-301 therapy is safe and well tolerated. This will be the first time HB-302/HB-301 will be tested in humans. HB-302/HB-301 has not yet been approved by the Food and Drug Administration (FDA).
Condition: Autoimmune Disorders / Rheumatoid Arthritis
Investigator: Jon Giles, MD
Status: Closed
We are inviting patients with active Rheumatoid Arthritis (RA) to help us better understand how treatment options affect inflammation in soft tissues. With a combination of blood work, a full-body FDG PET-CT scan, questionnaires, and a soft tissue biopsy (from an area around the belly button), we hope to see how RA interacts with these multiple areas of…
Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to determine the safety and efficacy of CMP-001 when given in combination with nivolumab for patients with unresectable (not capable of being surgically removed) or metastatic (cancer spreads to a different body part from where it started) melanoma. CMP-001 will be given as an injection into the tumor and nivolumab will be given…
Condition: Autoimmune Disorders
Investigator: Jon Giles, MD
Status: Closed
We are looking for patients who have been diagnosed with Psoriatic Arthritis (PsA) to help us better understand the involvement of inflammation on the body. With a combination of bloodwork, a bone density scan, questionnaires, and a one-time soft tissue biopsy (from an area around the belly button), we hope to see how PsA interacts with these multiple areas…
Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to test the study drug ALKS 4230 to see how well the drug works on patients with advanced cutaneous melanoma or subjects with advanced mucosal melanoma and have received prior treatment with an anti-programmed death-ligand 1 (anti-PD-L1) therapy, and your cancer has spread. This study will explore how well the drug works on…
Condition: Autoimmune Disorders
Investigator: Brian Henick, MD
Status: Closed
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere…
Study of Cabozantinib in Patients with Prostate Cancer who Previously Received Anti-Androgen Therapy
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of prostate cancer. Cabozantinib (Cometriq, Cabometyx) is an oral medication that blocks activity of specific proteins in the body. It is approved by the Food and Drug Administration (FDA) for use in patients with medullary thyroid carcinoma and advanced…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
This study aims to investigate ADXS-504 as a possible treatment for biochemically recurrent prostate cancer. ADXS-504 is a type of cancer treatment that is designed to stimulate your immune system to attack prostate cancer cells. ADXS-504 is made of bacteria that have been weakened to remove their ability to cause an infection. The bacteria have also been…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
This study is being done to learn if the study drug called Lutetium-177 PSMA I&T is safe and effective in patients with castration-resistant metastatic prostate cancer. The study drug contains radioactive Lutetium-177, which is targeted to treat certain prostate cancers cells that have a protein called the prostate-specific membrane antigen (PSMA) on…
Condition: Cancer / Skin Cancer
Investigator: Shaheer Khan, DO
Status: Closed
The purpose of this study is determine if cemiplimab will prevent Cutaneous Squamous Cell Cancer (CSCC) from returning after surgery and radiation.
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to find out whether delivering SBRT to the prostate, combined with the study drug atezolizumab, is a safe and effective treatment when given in combination with abiraterone, prednisone, and Lupron (the standard treatment for this disease). In addition, the researchers want to find out whether the study treatment works better…
Condition: Autoimmune Disorders
Investigator: Peter Green, MD
Status: Closed
This research study is sponsored by ImmunogenX and The National Institutes of Health (NIH, Bethesda, MD). The objective of this study is to determine if the investigational product (latiglutenase) will help decrease symptoms in subjects with celiac disease while maintaining a gluten-free diet while undergoing periodic gluten exposure. In addition, this…
Condition: Autoimmune Disorders
Investigator: Marcella Walker, MD
Status: Closed
Celiac disease is associated with an increased risk of osteoporosis and fractures. Men with celiac disease were found to be at higher risk for metabolic bone disease compared to women with celiac disease. The mechanisms underlying metabolic bone disease in celiac disease remain incompletely understood. The goal of this study is to assess skeletal…
Condition: Skin Cancer / Melanoma
Investigator: Brian Marr, MD
Status: Closed
The purpose of this research study is to test the safety and efficacy of AU-011 at different doses and different number of doses of study drug when it is injected into the suprachoroidal space of the eye with one or two laser light applications and to find out what effects, if any, it has on research participants with a choroidal melanoma tumor or…
Condition: Skin Cancer / Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
This study consists of two treatment groups, Part 1 and Part 2. The purpose of this study is to: Part 1 - Test the safety and tolerability of the study drug IN10018, see how well the drug works on your metastatic uveal melanoma, and see how your body handles the drug. Part 2 - Test the safety and tolerability of the study drug IN10018 with cobimetinib, see…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to see if a new, experimental drug called JNJ-75229414 is safe and useful for treating patients with metastatic castration-resistant prostate cancer. JNJ-75229414 is a Chimeric Antigen Receptor T Cell (CAR-T) cell therapy. This is the first time that JNJ75229414 will be used in humans. In this type of treatment, your white blood…
Condition: Cancer / Prostate Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to assess the effectiveness and safety of combining an investigational drug called BMS-986218 (also known as Anti-CTLA4-NF monoclonal antibody), or BMS-986218 plus nivolumab, with standard of care docetaxel (chemotherapy), in men who have metastatic castration-resistant prostate cancer (mCRPC) that progressed after a second-…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to determine if the addition of immunotherapy to the current standard of care for metastatic prostate cancer, chemotherapy, and hormonal therapy, is safe and improves your response to therapy. People who usually have metastatic prostate cancer to their bones and organs are usually treated with combination of chemotherapy (…
Condition: Cancer / Prostate Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to see whether immunotherapy with BMS-986218 added to degarelix (which suppresses your testosterone) given prior to surgery can decrease the chance that your cancer will come back compared to degarelix alone. People who usually have this type of prostate cancer usually do not receive any additional therapy prior to surgery.
Condition: Autoimmune Disorders / Rheumatoid Arthritis
Investigator: Laura Geraldino-Pardilla, MD, MPH
Status: Closed
This study aims to understand how two commonly prescribed drugs impact myocardial inflammation in rheumatoid arthritis.
Condition: Cancer / Skin Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the study is to determine the long-term effectiveness and safety of cemiplimab in patients diagnosed with Cutaneous Squamous Cell Carcinoma (CSCC, a type of skin cancer).
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
In Phase 1b, the purpose is to learn how well patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) tolerate the treatment when PLX2853 is added to ongoing treatment with abiraterone acetate and prednisone. We are looking for the highest dose of PLX2853 that can be given safely to patients with your type of disease who are already on…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to test the good and bad effects of the combined treatment, using the drugs cetuximab and avelumab as well as avelumab by itself. Avelumab is a drug that works by triggering the immune system so it can try to attack the cancer again. Avelumab works in a similar way to cemiplimab, which is the usual drug for treatment of your…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the effectiveness and safety of an experimental drug known as HPN424 (also known as study drug) in patients with advanced prostate cancer. This drug has been tested in animals but not yet in people. This study tests different doses of HPN424. We want to find out how good the drug is at treating prostate cancer. We also…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the study is to evaluate the effectiveness (how well the drug works) of the investigational drug called bempegaldesleukin when combined with drug nivolumab in comparison with nivolumab alone after complete resection (removal of all sites of known disease) of melanoma in participants at high risk of cancer returning after surgery (recurrence).
Condition: Skin Cancer / Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
This research study is a phase II clinical trial that will study the combination of adjuvant nivolumab and ipilimumab for the treatment of adult subjects with completely treated high-risk ocular melanoma. This study is being done to see if the combination of the study drugs is safe and effective in preventing the return of their cancer. If you are eligible…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
This study is for patients with prostate cancer and that require treatment because their disease is now growing. The purpose of this study is to see whether immunotherapy with nivolumab added to degarelix or nivolumab and BMS-986253 added to degarelix is safe and can decrease the chance that the cancer will come back. Degarelix is a standard of care drug…
Condition: Autoimmune Disorders
Investigator: Runsheng Wang, MD
Status: Closed
This is a 6-week randomized, double-blind trial of 4 different non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis to compare the change of pain score from baseline at 4 weeks to the change of pain score from baseline at 6 weeks. Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion and…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
If you have active Systemic Lupus Erythematosus, also known as SLE or Lupus, you may be interested to learn about a clinical research study that is being conducted to study the safety and effectiveness of an investigational medication called ustekinumab for active Lupus. Eligible study participants will be provided with study medication and study-related…
Condition: Cancer / Prostate Cancer
Investigator: Charles Drake, MD
Status: Closed
We are doing this study to test a drug called MGD009. MGD009 is like an antibody, which is a protein in your blood that helps get rid of germs in your body. MGD009 is made to attach to cancer cells and to T-cells, which are a part of your immune system. Certain T cells have the ability to kill other cells, including cancer cells. By attaching to cancer…
Condition: Autoimmune Disorders
Investigator: Anca Askanase, MD, MPH
Status: Closed
In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks.
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the first part (Phase I) of the study is to test the safety of navitoclax in combination with dabrafenib and trametinibat different doses to find out what effects, if any, it has on people. There will be about 18 people treated in this part of the study. The purpose of the second part of this study (Phase II) is to compare the good and bad…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
You are being asked to participate in this research study because you have been diagnosed with metastatic castrate resistant prostate cancer (mCRPC) and are scheduled to start a new treatment. The purpose of this study is to see if changes in 18FDCFPyL (PyL) PET/CT scans before starting your new treatment and after 6 weeks on treatment is associated with…
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Closed
Systemic sclerosis (SSc) is a systemic connective tissue disease characterized by fibrosis and atrophy, namely of the skin, internal organs, joints, and skeletal muscles. There are numerous manifestations of SSc that affect multiple organ systems. The major pulmonary manifestations of SSc, interstitial lung disease and systemic sclerosis-associated…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to gather information on the safety of TH-302 and its effect on your cancer. This study will also look at how the drug is processed in the body. In addition, this study will collect data from blood, tumor, and imaging studies about your specific cancer such as the level of oxygen that is present. This may help us understand…
Condition: Autoimmune Disorders / Rheumatoid Arthritis
Investigator: Joan Bathon, MD
Status: Closed
The study aims to compare the effect two different RA treatments on cardiovascular health in patients who are considering a treatment change. The study is recruiting patients who are only taking methotrexate and are switching treatment due to a lack of improvement. The trial will randomize participants to take a TNF inhibitor (Enbrel or Humira) in addition…
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Closed
The purpose of this study is to determine the effectiveness and safety of a study drug called abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The study will also look at the following: How the study drug affects other symptoms of SSc-ILD -How safe the study drug is (i.e. if there are any side effects) -How the…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to find out more about the Amgen agent called talimogene laherparepvec in people with advanced melanoma when given in combination with another drug developed by Merck called pembrolizumab. Melanoma is a type of skin cancer. Advanced melanoma means the tumor is not removable by surgery or has spread to other parts of the body.
Condition: Skin Cancer / Melanoma
Investigator: Larisa Geskin, MD
Status: Closed
The purpose of this study is to determine how effective and safe the immune drug Nivolumab is for patients who have newly diagnosed cutaneous melanoma. Nivolumab is an anti-body, a type of human protein, that is being tested to see if it will allow the body's immune system to work against tumor cells. If you are eligible for the study, you will…
Condition: Cancer / Prostate Cancer
Investigator: Emerson Lim, MD
Status: Closed
You are being asked to join this study because you have either been diagnosed with prostate cancer and will be having surgery to remove your prostate or you will be having a prostate biopsy to look for prostate cancer. This study is looking to see if a new imaging device, diffuse optical tomography (DOT), can detect prostate cancer. We will also see if DOT…
Condition: Autoimmune Disorders / Lupus
Investigator: Wooin Ahn, MD
Status: Closed
The purpose of this study is to determine if Acthar gel is a safe and effective therapy for patients with membranous (Class V) lupus nephritis. Class V lupus nephritis is associated with the development of chronic kidney disease and end-stage renal (kidney) disease, and there is no clear therapy for treatment. Currently used therapies arent completely…
Condition: Cancer / Skin Cancer
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to examine the effects of KPT-330 on patients with an advanced form of skin cancer called Squamous Cell Cancer (SCC) of the head and neck, lung, or esophagus. The study drug KPT-330 is an investigational drug that
Condition: Autoimmune Disorders / Rheumatoid Arthritis
Investigator: Joan Bathon, MD
Status: Closed
We are doing a research study to learn more about why people with rheumatoid arthritis (RA) are prone to heart disease. We are recruiting patients diagnosed with Rheumatoid Arthritis without a personal history of heart disease. This study involves one initial full visit as described below, and a brief follow up visit that will take place approximately 2 or…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called nivolumab when combined with rucaparib, docetaxel or enzalutamide in participants with late stage prostate cancer that was unable to be surgically removed. These three combinations: nivolumab plus rucaparib, nivolumab…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
The purpose of this study is to test the safety and effectiveness of the study drug Obinutuzumab and to find out what effects, good or bad, it may have as an additional therapy in treating your lupus nephritis symptoms.
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
This is a phase II research study for individuals with resectable, stage IIIB to IVM1a Melanoma. The research drug being studied is talimogene laherparepvec. Talimogene laherparepvec is still experimental and has not been approved by the Food and Drug Administration (FDA) for use in people with melanoma. The purpose of this study is to find out more about…
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Closed
The purpose of this study is to find out whether a drug called iloprost is safe to use in people with systemic sclerosis (SSc) (Raynaud's phenomenon), and whether it may help decrease symptomatic digital ischemic episodes (episodes in the fingers).
Condition: Cancer / Prostate Cancer
Investigator: Charles Drake, MD
Status: Closed
The purpose of this clinical trial to find out if the investigational medication pembrolizumab in combination with enzalutamide + Androgen Deprivation Therapy (ADT) is safe and works to slow down or stop the growth of metastatic prostate cancer compared to enzalutamide + ADT alone. Pembrolizumab is a type of immunotherapy, which may help the bodys immune…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to find out which participants with melanoma respond best to nivolumab and ipilimumab treatment and to identify tumor and blood based markers that may predict response to the combination. This study is asking that participants submit tumor tissue samples from their initial tumor specimen and blood samples before they receive…
Condition: Cancer / Prostate Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This research study will look at whether computer tools (also called decision aids) help prostate cancer patients better understand their treatment options and help patients talk about their treatment preferences with their doctors
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
This study is for patients who have been diagnosed with systemic Lupus erythematosus (SLE). SLE is a disease in which the body mistakenly attacks healthy tissue. It can affect the skin, joints, kidneys, brain and other organs. The purpose of this study is to test the effects of an investigational (being tested) study drug, CC 220, in order to find out if CC…
Condition: Skin Cancer / Melanoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to find out if the drugs LEE011 and MEK162, administered in combination, are safe and effective in treating people who have melanoma. Specifically, this study will evaluate the effects of the combination of the two drugs, LEE011 and MEK162, in melanoma, carrying specific mutation in a gene called NRAS. The changes in the NRAS…
Condition: Autoimmune Disorders / Lupus
Investigator: Lisa Imundo, MD
Status: Closed
The purpose of the study is to find out if study drug belimumab is safe and effective in treating children with active lupus who are also taking other lupus medicine. Belimumab (also known as BENLYSTA hasbeen approved in the United States, Canada, and Europe for the treatment of adults with active SLEwho are receiving other lupus medicines but not yet…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for adult subjects with head and neck cancer (oral cavity, oropharynx middle part of the throat, hypopharynx bottom part of the throat, or larynx part of throat between the base of the tongue and the windpipe) that has either returned after treatment (recurrent) or is newly diagnosed. If newly diagnosed, the cancer must be metastatic,…
Condition: Cancer / Prostate Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of this study is to find a more effective treatment as well as to gain a better understanding of prostate cancer. This study includes investigational study drugs which are specific for your prostate cancer (module). Treatment in each module will include an investigational medication called AZD4635 as well as another module-specific study drug(s…
Condition: Skin Cancer / Melanoma
Investigator: Brian Marr, MD
Status: Closed
The purpose of this research study is to test the safety of Light-activated AU-011 at three different doses of the study drug and repeat dose regimens (two or three doses of highest safe dose) to find out what effects, if any, it has on research participants with a choroidal melanoma tumor. This study will have a high dose, a medium dose, and a low dose of…
Condition: Cancer / Prostate Cancer
Investigator: Sven Wenske, MD
Status: Closed
This study is being conducted to evaluate the performance of the ConfirmMDx and SelectMDx tests for Prostate Cancer to identify patients with increased risk for clinically significant disease, to ultimately lower the rate of repeat biopsies. Approximately 1000 people are expected to take part in this study.
Condition: Cancer / Prostate Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This study will enroll participants with prostate cancer that were treated by removing the prostate or by giving radiation (or both), but whose blood prostate specific antigen (PSA) level is going up. PSA is produced by the prostate and other tissues, and when it goes up, it means that the prostate cancer is coming back. In this study, participants will…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
The purpose of this study is to evaluate the safety and tolerability of an experimental investigational drug called ixazomib citrate (MLN9708) in patient with Lupus Nephritis. Lupus nephritis is a condition when the kidney is affected in the autoimmune disease known as systemic lupus erythematosus (SLE). SLE is a disease in which the immune system (the body…
Study for subjects with untreated Melanoma using trial drugs Talimogene Laherparepvec and Ipilimumab
Condition: Cancer / Skin Cancer
Investigator: Bret Taback, MD
Status: Closed
The purpose of this study is to find out more about talimogene laherparepvec (formerly known as OncoVEXGM-CSF), in people with advanced melanoma when given in combination with another drug called ipilimumab. Melanoma is a type of skin cancer. Advanced melanoma means the tumor is not removable by surgery or has spread to other parts of the body. Phase 1 of…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to see if 18FDCFPyL (PyL) PET/CT scans are able to find prostate cancer tumors. PyL is a radioactive drug (tracer) that targets prostate specific membrane antigen (PSMA). Because PSMA is a protein found mostly on the surface of prostate cancer cells, we are testing to see if PyL will be able to correctly identify prostate cancer…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
The goal of this study is to test a new lupus drug. This drug interrupts the function of a chemical in the body called IL-6, and IL-6 may be overactive in people with lupus. ALX-0061 is a study drug that will be administered subcutaneously to subjects with moderate to severe active, seropositive Systemic Lupus Erythematosus (SLE) compared to placebo.
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with melanoma, non-small cell lung cancer (NSCLC), or squamous cell cancer of the head and neck (SCCHN) that has a protein called B7-H3 on the tumor cells or blood vessels in thetumor. The purpose of this study is to test the safety, tolerability, and most effective dose ofMGA271 in combination with ipilimumab (also called Yervoy…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to compare the efficacy and safety of cobimetinib plus atezolizumab with the efficacy and safety of pembrolizumab in patients with a type of skin cancer called melanoma that has spread to other parts of the body (metastatic), cannot be removed by surgery (unresectable), and have not received any prior treatment.
Condition: Cancer / Prostate Cancer
Investigator: Sven Wenske, MD
Status: Closed
The goal of this study is to evaluate how the results of a novel laboratory developed and validated urine test which predicts the likelihood of high grade prostate cancer will impact the decision on whether you will have a prostate biopsy to rule out prostate cancer. Approximately 1,000 subjects will be enrolled in this study. The study is expected to last…
Condition: Cancer / Prostate Cancer
Investigator: Edward Gelmann, MD
Status: Closed
The purpose of this study is to compare the clinical benefit (i.e., does it help to improve or slow down the cancer) of adding study drug JNJ-56021927 to combined treatment of abiraterone acetate plus prednisone to treat patients with metastatic Castration-resistant Prostate Cancer (mCRPC). This study will also evaluate the possible side effects of study…
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Closed
The purpose of this study is to determine the efficacy and safety of abituzumab in subjects withsystemic sclerosis-associated interstitial lung disease (SSc-ILD).Abituzumab is an investigational drug that is being evaluated for the treatment of patients withsystemic sclerosis (SSc)-associated interstitial lung disease (SSc-ILD). Systemic sclerosis,…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this research study is to determine if high-dose versus standard-dose regimens of encorafenib and binimetinib are safe and have positive effects in people who have melanoma brain metastasis and also have been found by their doctor to have a mutated gene called BRAFV600. The time frame for the study is approximately 2 years.
Condition: Autoimmune Disorders
Investigator: Thomas Brannagan, MD
Status: Closed
This study is for patients with Lambert-Eaton Myasthenic Syndrome (LEMS). The purpose of this study is to provide doctors and their patients access to amifampridine phosphate therapy for their patients with LEMS, CMS or downbeat nystagmus until the product becomes commercially available. The secondary purpose of the study is to assess the long-term safety…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for patients with recurrent or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). This study will test the safety of an experimental anti-cancer drug (MEDI4736). MEDI4736 is an antibody (a protein produced by the defense system of the body immune system) that has been made in the laboratory. MEDI4736 boosts the ability of your…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
We are studying a medication to see if it is effective in reducing the disease activity of systemic lupus erythematosus (SLE), which is the most common form of lupus. You may qualify for the Achtar study if you have persistently active SLE, are 18 years of age or older, and: Have rash and/or arthritis as part of your SLE symptoms Are currently taking…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
This research study is investigating a new treatment for cancer that uses your immune system (a type of white blood cell called T cells or T lymphocytes) to try to attack your cancerous cells. T cells fight infections, and may attack cancer cells, in some cases. Currently, your T cells may not able to attack your cancerous cells. The use of these modified T…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
The purpose of this clinical trial is to learn about the ability of an experimental treatment XmAb5871 to maintain lupus disease activity improvement achieved by a brief course of disease-suppressing intramuscular (IM) steroid therapy in lupus patients.
Condition: Cancer / Prostate Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of this study is to find out if ODM-201 is effective at keeping hormone-sensitive prostatecancer under control when given in addition to standard treatment which includes androgen deprivation therapy (ADT) and docetaxel chemotherapy for six cycles. A total of approximately 1,300 men will take part in this study at a number of different locations…
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Closed
Systemic sclerosis (SSc) is a systemic connective tissue disease characterized by fibrosis and atrophy, namely of the skin, internal organs, joints, and skeletal muscles. This is a double-blind, placebo-controlled trial to test the efficacy of abatacept (Orencia) on the treatment of diffuse cutaneous systemic sclerosis in patients with a disease duration of…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to determine the effectiveness and safety of study drug MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 and tremelimumab combination therapy in the treatment of patients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck who have progressed during or after treatment with…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE